文献速递心血管技术与安全USMR

法布雷病左心室质量与壁厚:超声与心脏磁共振测量差异的临床意义

Left Ventricular Mass and Wall Thickness Measurements Using Echocardiography and Cardiac MRI in Patients with Fabry Disease: Clinical Significance of Discrepant Findings.
PubMed 文献 · Radiol Cardiothorac Imaging · 2020-06-11

回顾性纳入78例法布雷病患者,比较6个月内经胸超声与心脏磁共振测量的左心室质量指数和最大壁厚。超声测值显著高于磁共振,导致29%患者左心室肥厚分类不一致、26%患者疾病特异性治疗资格判定不一致;磁共振测值的预后预测与观察者间一致性更优。

要点

  • 法布雷病中超声测左心室质量指数和最大壁厚均显著高于心脏磁共振。
  • 两种方法致29%患者左心室肥厚分类不一致、26%治疗资格判定不一致。
  • 磁共振测左心室质量指数对复合终点的预测优于超声,观察者间一致性更高。

核心结论

  • 在法布雷病中,超声高估左心室质量和最大壁厚,重复性低于心脏磁共振。
  • 两种方法测量差异对左心室肥厚诊断、预后及治疗决策具有临床意义。
  • 磁共振测量的左心室质量指数对复合终点的预测优于超声(AIC 127 vs 131)。

研究设计与样本

  • 回顾性队列研究,纳入78例法布雷病患者(平均年龄46岁±14,女性63%)。
  • 患者均在2008至2018年间6个月间隔内接受经胸超声和心脏磁共振检查。
  • 统计方法包括配对样本t检验、Cox比例风险模型、AIC和组内相关系数。

关键影像表现/征象

  • 超声测左心室质量指数105 g/m2±48 vs 磁共振78 g/m2±36(P < .001),超声显著更高。
  • 超声测最大壁厚14 mm±4 vs 磁共振13 mm±5(P = .008),超声显著更高。

诊断标准与关键数值

  • 左心室肥厚分类在23例(29%)患者中两种方法不一致(P < .001)。
  • 基于最大壁厚的疾病特异性治疗资格在20例(26%)患者中两种方法不一致(P < .001)。
  • 左心室质量指数观察者间组内相关系数:磁共振0.951 vs 超声0.940。
  • 最大壁厚观察者间组内相关系数:磁共振0.912 vs 超声0.871。

临床应用与阅片要点

  • 法布雷病评估左心室质量指数和最大壁厚时,需注意超声测值系统性高于磁共振。
  • 左心室肥厚分类及疾病特异性治疗资格判定可能因检查方法不同而改变。
  • 磁共振测左心室质量指数对复合终点预测更优,观察者间一致性更高。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

PURPOSE: To compare transthoracic echocardiography (TTE) and cardiac MRI measurements of left ventricular mass (LVM) and maximum wall thickness (MWT) in patients with Fabry disease and evaluate the clinical significance of discrepancies between modalities.

MATERIALS AND METHODS: Seventy-eight patients with Fabry disease (mean age, 46 years ± 14 [standard deviation]; 63% female) who underwent TTE and cardiac MRI within a 6-month interval between 2008 and 2018 were included in this retrospective cohort study. The clinical significance of measurement discrepancies was evaluated with respect to diagnosis of left ventricular hypertrophy (LVH), eligibility for disease-specific therapy, and prognosis. Statistical analysis included paired-sample t test, Cox proportional hazard models, Akaike information criterion (AIC), and intraclass correlation coefficients.

RESULTS: LVM indexed to body surface area (LVMI) and MWT were significantly higher at TTE compared with MRI (105 g/m2 ± 48 vs 78 g/m2 ± 36, P < .001 and 14 mm ± 4 vs 13 mm ± 5, P = .008, respectively). LVH classification was discordant between modalities in 23 patients (29%) (P < .001). Eligibility for disease-specific therapy based on MWT was discordant between modalities in 20 patients (26%) (P < .001). LVMI assessed with MRI was a better predictor of the combined endpoint compared with LVMI assessed with TTE (AIC, 127 vs 131). Interobserver agreement for LVMI and MWT was higher for MRI (intraclass correlation coefficient, 0.951 and 0.912, respectively) compared with TTE (intraclass correlation coefficient, 0.940 and 0.871; respectively).

CONCLUSION: TTE overestimates LVM and MWT and has lower reproducibility compared with cardiac MRI in Fabry disease. Measurement discrepancies between modalities are clinically significant with respect to diagnosis of LVH, prognosis, and treatment decisions.© RSNA, 2020.

来源:Radiol Cardiothorac Imaging,查看原文。版权归原作者所有。

引用

  1. O'Brien C, Britton I, Karur GR, et al. Left Ventricular Mass and Wall Thickness Measurements Using Echocardiography and Cardiac MRI in Patients with Fabry Disease: Clinical Significance of Discrepant Findings. Radiol Cardiothorac Imaging. 2020. PMID: 33778580. doi:10.1148/ryct.2020190149

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。